Drugs / Idursulfase-ß
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05422482 | Sep 2022 → Jun 2027 expected | mucopolysaccharidosis type 2 | GC Biopharma Corp | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Idursulfase-ß | “ICV-administered Hunterase, Idursulfase-ß” NCT05422482 ↗ |
| Known as | Hunterase | “ICV-administered Hunterase, Idursulfase-ß” NCT05422482 ↗ |